Regenerative Medicine: PRP and Stem Cell Therapy in Orthopedics

Regenerative medicine encompasses biologic therapies designed to stimulate the body's own repair mechanisms rather than replacing or removing damaged tissue. In orthopedics, platelet-rich plasma (PRP) and stem cell therapies are the two most established categories, applied to conditions ranging from tendon injuries to cartilage degeneration. Understanding how these treatments work, where the evidence supports their use, and how the U.S. Food and Drug Administration (FDA) frames their regulatory status is essential for any informed evaluation of these options.

Definition and scope

Regenerative orthopedic therapies fall under the broader umbrella of biologics — substances derived from living cells or tissues intended to promote healing at the molecular or cellular level. The orthopedics field has adopted two primary categories:

Platelet-Rich Plasma (PRP): A preparation derived from the patient's own blood, centrifuged to concentrate platelets to levels typically 3 to 8 times above baseline whole blood concentration. Platelets carry growth factors — including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF) — that regulate tissue repair signaling.

Stem Cell Therapy: Involves the introduction of undifferentiated or progenitor cells capable of differentiating into specialized tissue types. In orthopedics, the two most common sources are:
- Bone marrow aspirate concentrate (BMAC): Harvested from the patient's iliac crest, concentrated to yield mesenchymal stem cells (MSCs) alongside hematopoietic progenitors.
- Adipose-derived stem cells: Isolated from fat tissue via lipoaspiration, then processed to extract a stromal vascular fraction containing MSCs.

The FDA classifies most autologous (same-patient) PRP and BMAC preparations under the "minimal manipulation" and "homologous use" standards established in 21 CFR Part 1271 (FDA Human Cells, Tissues, and Cellular and Tissue-Based Products regulations). Preparations that undergo more than minimal manipulation — such as expanded cell cultures or allogeneic (donor) cell lines — trigger full Biologics License Application (BLA) requirements under the Public Health Service Act, Section 351.

How it works

Both PRP and stem cell therapies share a mechanism logic: they introduce high concentrations of bioactive agents to a site of injury or degeneration that has limited intrinsic healing capacity.

PRP mechanism (step-by-step):
1. Approximately 30–60 mL of venous blood is drawn from the patient.
2. The sample undergoes a double-spin centrifuge protocol, separating red blood cells, platelet-poor plasma, and the platelet-rich layer (the "buffy coat" zone).
3. The resulting PRP concentrate — typically 3–8 mL — is injected under ultrasound guidance into the target structure (tendon, joint, or ligament).
4. Activated platelets degranulate, releasing growth factors that recruit fibroblasts and stimulate collagen synthesis.
5. Leukocyte content in the PRP (classified as leukocyte-rich vs. leukocyte-poor) influences the inflammatory profile of the response; leukocyte-poor formulations are generally preferred for intra-articular injections per research published in the American Journal of Sports Medicine.

Stem cell mechanism:
BMAC injections introduce MSCs that can secrete paracrine signaling molecules — anti-inflammatory cytokines and growth factors — which modulate the local tissue environment. True trans-differentiation into chondrocytes or tenocytes in vivo is mechanistically possible but remains incompletely characterized in human clinical trials as of the published literature reviewed by the National Institutes of Health's National Center for Complementary and Integrative Health (NCCIH).

Common scenarios

Regenerative injections are applied across a defined set of orthopedic diagnoses where conventional conservative care has plateaued and surgical intervention carries disproportionate risk or recovery burden.

Tendon pathology: PRP has the strongest published evidence base for chronic lateral epicondylitis (tennis elbow) and patellar tendinopathy. A 2021 systematic review indexed in PubMed demonstrated superior pain reduction for PRP versus corticosteroid injection at 6-month follow-up for lateral epicondylitis. Cortisone injections remain the comparative standard against which PRP trials are typically benchmarked.

Osteoarthritis: Intra-articular PRP for knee osteoarthritis is among the most studied applications. The American Academy of Orthopaedic Surgeons (AAOS) 2021 Clinical Practice Guidelines on knee osteoarthritis included PRP as an "inconclusive" recommendation — acknowledging benefit signals without sufficient trial homogeneity for a strong recommendation (AAOS Clinical Practice Guidelines).

Rotator cuff injuries: Both PRP and BMAC have been studied as adjuncts to surgical repair of rotator cuff tears, with the hypothesis that biologic augmentation at repair sites improves tendon-to-bone healing rates.

Cartilage defects: Stem cell injections have been investigated for focal chondral defects in the knee and hip labral tears and impingement contexts, primarily in patients who are not candidates for resurfacing procedures.

Decision boundaries

The regulatory and clinical evidence frameworks create clear classification lines that affect when these therapies are appropriate versus investigational.

Regulatory classification determines access:
- Autologous, minimally manipulated PRP and BMAC processed at the point of care are generally permissible under the FDA's 21 CFR Part 1271 framework without a BLA.
- Commercially expanded allogeneic stem cell products require FDA licensure. The FDA has issued untitled letters and warning letters to multiple providers marketing unlicensed allogeneic stem cell products, documented in the FDA's Biological Product Deviation database (FDA Biologics Compliance).
- The regulatory context for orthopedics governs how facilities and practitioners must document, handle, and administer these preparations under applicable federal standards.

Payer coverage is structurally limited: Medicare and most commercial insurers classify PRP as non-covered for the majority of orthopedic indications, citing insufficient evidence under Coverage with Evidence Development criteria. Exceptions exist for specific wound care indications.

Patient selection criteria:

1. Failed conservative management for a minimum defined duration (typically 3–6 months for tendinopathies).
2. Absence of active systemic infection or malignancy, which contraindicate biologic amplification therapies.
3. Platelet counts within therapeutic range (generally >100,000/μL) for PRP candidacy.
4. Absence of coagulopathy or anticoagulant therapy that would compromise platelet function.
5. Confirmed structural diagnosis via MRI or ultrasound — treatment of an uncharacterized pain generator without imaging confirmation is considered outside the standard of care.

PRP versus stem cell therapy — key distinctions:

Cost figures reflect published patient-facing ranges reported by academic medical center transparency disclosures; individual pricing varies by facility and geographic market.

The distinction between evidence-supported and investigational use is the operative threshold. Providers operating under hospital or academic credentialing systems are required to obtain IRB oversight for stem cell applications that fall outside cleared or licensed indications, per FDA guidance on human subject research protections under 21 CFR Part 50 (FDA Human Subject Protections).

References

• FDA 21 CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products
• FDA Biologics Compliance — Enforcement Actions
• FDA Human Subject Protections — 21 CFR Part 50
• NCCIH — Stem Cell Therapy
• AAOS Clinical Practice Guidelines — Knee Osteoarthritis (2021)
• [NIH National Library of Medicine

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)